Endometrial cancer and antidepressants A nationwide population-based study

Medicine (United States)

Volumn 95, Issue 29, 2016, Pages

  Lin, Chiao Fan ^a,b   Chan, Hsiang Lin ^a,b   Hsieh, Yi Hsuan ^a,b   Liang, Hsin Yi ^a,b   Chiu, Wei Che ^c   Huang, Kuo You ^d   Leee, Yena ^e   McIntyre, Roger S ^e,f   Chen, Vincent Chin Hung ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CATHAY GENERAL HOSPITAL   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antidepressants; Endometrial cancer; Taiwan national insurance

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOSULEPIN; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MELITRACEN; MIRTAZAPINE; MOCLOBEMIDE; PAROXETINE; RASAGILINE; SERTRALINE; TRAZODONE; VENLAFAXINE;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DRUG EXPOSURE; ENDOMETRIUM CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; MIDDLE AGED; NATIONAL HEALTH INSURANCE; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; CASE CONTROL STUDY; ENDOMETRIAL NEOPLASMS; EPIDEMIOLOGY; INCIDENCE; RISK FACTOR; TAIWAN; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; RISK FACTORS; TAIWAN;

EID: 84980042086     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000004178     Document Type: Article

References (26)

1. Graziottin A, Serafini A. Depression and the menopause: why antidepressants are not enough? Menopause Int 2009;15:76-81.
2. Pae CU, Mandelli L, Kim TS, et al. Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects. Biomed Pharmacother 2009;63:228-35.
3. Bahl S, Cotterchio M, Kreiger N. Use of antidepressant medications and the possible association with breast cancer risk. A review. Psychother Psychosom 2003;72:185-94.
4. Dalton SO, Johansen C, Mellemkjaer L, et al. Antidepressant medications and risk for cancer. Epidemiology 2000;11:171-6.
5. Cosgrove L, Shi L, Creasey DE, et al. Antidepressants and breast and ovarian cancer risk: a review of the literature and researchers' financial associations with industry. PLoS One 2011;6:e18210.
6. Taler M, Gil-Ad I, Lomnitski L, et al. Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol 2007;17: 774-80.
7. Abdul M, Logothetis CJ, Hoosein NM. Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol 1995;154:247-50.
8. Wu CS, Lu ML, Liao YT, et al. Ovarian cancer and antidepressants. Psychooncology 2015;24:579-84.
9. Ashbury JE, Levesque LE, Beck PA, et al. Selective serotonin reuptake inhibitor (SSRI) antidepressants, prolactin and breast cancer. Front Oncol 2012;2:177.
10. Steingart AB, Cotterchio M. Do antidepressants cause, promote, or inhibit cancers? J Clin Epidemiol 1995;48:1407-12.
11. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
12. Kato I, Zeleniuch-Jacquotte A, Toniolo PG, et al. Psychotropic medication use and risk of hormone-related cancers: the New York University Women's Health Study. J Public Health Med 2000;22:155-60.
13. Fortuny J, Sima C, Bayuga S, et al. Risk of endometrial cancer in relation to medical conditions and medication use. Cancer Epidemiol Biomarkers Prev 2009;18:1448-56.
14. Welfare MoHaOverview of National Health Insurance. Taipei, Taiwan: Welfare MoHa; 2013.
15. Wacholder S, Silverman DT, McLaughlin JK, et al. Selection of controls in case-control studies. III. Design options. Am J Epidemiol 1992;135:1042-50.
16. WHO. Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs, 2013 (Available from: http://www.whocc.no/atc-ddd-publications/atc-ddd-index/.) [Accessed July 10, 2014].
17. Reeves KW, Okereke O, Qian J, et al. Depression and antidepressant use in relation to breast cancer risk in the Nurses Health Study. Cancer Epidemiol Biomarkers Prev 2015;24:761-2.
18. Chen VC, Liao YT, Yeh DC, et al. Relationship between antidepressant prescription and breast cancer: a population based study in Taiwan. Psychooncology 2015.
19. Eom CS, Park SM, Cho KH. Use of antidepressants and the risk of breast cancer: a meta-analysis. Breast Cancer Res Treat 2012;136:635-45.
20. Harlow BL, Cramer DW. Self-reported use of antidepressants or benzodiazepine tranquilizers and risk of epithelial ovarian-cancer-evidence from 2 combined case-control studies (Massachusetts, United States). Cancer Cause Control 1995;6:130-4.
21. Harlow BL, Cramer DW, Baron JA, et al. Psychotropic medication use and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 1998;7:697-702.
22. Wu CS, Lu ML, Liao YT, et al. Ovarian cancer and antidepressants. Psychooncology 2015;24:579-84.
23. Amerio A, Galvez JF, Odone A, et al. Carcinogenicity of psychotropic drugs: a systematic review of US Food and Drug Administration-required preclinical in vivo studies. Aust N Z J Psychiatry 2015;49: 686-96.
24. Chubak J, Doherty JA, Cushing-Haugen KL, et al. Endometrial cancer risk in estrogen users after switching to estrogen-progestin therapy. Cancer Cause Control 2007;18:1001-7.
25. Zhou B, Yang L, Sun Q, et al. Cigarette smoking and the risk of endometrial cancer: a meta-analysis. Am J Med 2008;121:501-8.e3.
26. Furberg AS, Thune I. Metabolic abnormalities (hypertension, hypergly-cemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. Int J Cancer 2003;104:669-76.